One-year evaluation of recombinant human tumor necrosis factor-alpha receptor II decrement combined with thalidomide increment in the treatment of active ankylosing spondylitis

Authors
Category Primary study
JournalChinese Journal of Tissue Engineering Research
Year 2019
This article has no abstract
Epistemonikos ID: 1c7fe57b71421f8e66625bbaa69ee44dc35aa88b
First added on: Feb 11, 2025